<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chagas gastrointestinal disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chagas gastrointestinal disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chagas gastrointestinal disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rogelio López-Vélez, MD, DTMH, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter F Weller, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nicholas J Talley, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 12, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H86302849">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chagas disease is caused by infection with the protozoan parasite
         <em>
          Trypanosoma cruzi
         </em>
         ; the major manifestations are Chagas cardiomyopathy and gastrointestinal disease [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Issues related to the epidemiology and prevention of Chagas disease, acute and chronic Chagas infection, and cardiac Chagas are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5698.html" rel="external">
          "Chagas disease: Epidemiology, screening, and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114181.html" rel="external">
          "Chagas disease: Acute and congenital Trypanosoma cruzi infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114192.html" rel="external">
          "Chagas disease: Chronic Trypanosoma cruzi infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4955.html" rel="external">
          "Chronic Chagas cardiomyopathy: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4925.html" rel="external">
          "Chronic Chagas cardiomyopathy: Management and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3660898">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among individuals with the chronic indeterminate form of Chagas disease, approximately 30 percent progress over a period of one to three decades to clinically evident cardiac involvement, digestive involvement, or both [
         <a href="#rid2">
          2
         </a>
         ]. Gastrointestinal involvement is less common (10 to 21 percent). The mortality associated with Chagas gastrointestinal disease is low, but symptoms can considerably impact the quality of life. It is relatively rare in the setting of reactivation of chronic
         <em>
          T. cruzi
         </em>
         infection among organ transplant recipients or in patients with HIV infection, although there are reports of parasitic invasion of the peritoneum, intestine, stomach, esophagus, or larynx. (See
         <a class="medical medical_review" href="/z/d/html/114195.html" rel="external">
          "Chagas disease in the immunosuppressed host"
         </a>
         .)
        </p>
        <p>
         The likelihood of digestive involvement may vary by region [
         <a href="#rid3">
          3
         </a>
         ]. The digestive form is observed more frequently in the countries of the Southern Cone of South America and is rare in northern South America, Central America, and Mexico [
         <a href="#rid4">
          4
         </a>
         ]. A high prevalence has been observed in the central region of Brazil. This geographic pattern is thought to be due to the distribution of different
         <em>
          T. cruzi
         </em>
         genotypes [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The burden of the gastrointestinal form can be enormous for some countries. In one study that evaluated hospitalization rates due to Chagas disease in Brazil between 2017 to 2019, there were 0.6 hospitalizations per 100,000 inhabitants, with significant regional variation. Hospitalizations increased with age and were slightly higher in males. More than 60 percent were emergencies and 50 percent were surgical procedures. In-hospital mortality was 5.8 percent and 17.2 percent went to intensive care units [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         However, the risk for travelers to endemic countries is extremely low (≤0.8 per 1000 traveler-days) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H86302856">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both parasite and host factors are thought to influence the development of gastrointestinal manifestations and the severity of disease. Molecular techniques have demonstrated the presence of parasite DNA in digestive tissues, which correlates with inflammatory infiltrate and degree of denervation [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         The parasite burden likely influences the degree of inflammation and progression of disease. In addition to parasite-dependent inflammation, there is an immune-mediated tissue injury resulting from cross-reactivity between parasite antigens and enteric neuron surface proteins [
         <a href="#rid10">
          10
         </a>
         ]. Moreover, the occurrence of gastrointestinal manifestations in certain geographical areas has been attributed to variations in parasite strains [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         The pathogenesis of disease consists of destruction of the neurons of the enteric nervous system. Both sympathetic and parasympathetic nerves are involved, and denervation occurs in both the submucosal (Meissner) and myenteric (Auerbach) plexuses. A significant reduction in the number of interstitial cells of Cajal has been demonstrated; these cells play an important role in the modulation of digestive tube motility. Histologically, neuronal reduction and focal areas of fibrosis in the smooth muscle and myenteric plexuses have been described, along with lymphocytic infiltrates at the submucosal, myenteric plexus, and smooth muscle levels. In addition, the muscularis mucosa can become hypertrophic, likely a compensatory mechanism [
         <a href="#rid12">
          12
         </a>
         ]. Denervation occurs to variable degrees; it is irregular and noncontinuous. The esophagus and the distal colon are the most frequently involved segments.
        </p>
        <p>
         The digestive form of Chagas disease is characterized by alterations in the motor, secretory, and absorptive functions of the gastrointestinal tract. Uncoordinated motor activity of the sphincters occurs as a result of denervation. In the esophagus, there is hypercontractility and increased muscular tone, and often there is failure of sphincter relaxation with swallowing. In the large intestine, there is abnormal basal colonic motility and impaired relaxation of the anal sphincter. Progressive dilation of the esophagus and colon occurs, with reduction of contractility [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p>
         Cellular interactions and molecular pathways involved in megacolon development/progression are not completely clear. Several biomarkers and their possible functions in the intestinal microenvironment of the chagasic megacolon have been described [
         <a href="#rid15">
          15
         </a>
         ]. The presence of NOD2 innate immune receptors seems to play a protective role against the development of the digestive form of Chagas disease [
         <a href="#rid16">
          16
         </a>
         ]. It has been suggested that
         <em>
          T. cruzi
         </em>
         infection results in alterations to the intestinal microbiome, which play a role in inflammation [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H86302863">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transient gastrointestinal symptoms (eg, dysphagia and retrosternal pain, abdominal pain, and diarrhea) can occur during the acute phase of infection [
         <a href="#rid18">
          18,19
         </a>
         ]. However, significant gastrointestinal manifestations of Chagas disease are mainly associated with the chronic phase of infection. Manifestations range from asymptomatic motility disorders to severe dilatation of the esophagus and colon. (See
         <a class="medical medical_review" href="/z/d/html/114192.html" rel="external">
          "Chagas disease: Chronic Trypanosoma cruzi infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1338571713">
         <span class="h2">
          Disease onset and progression
         </span>
         <span class="headingEndMark">
          —
         </span>
         The onset of symptoms is most common between the ages of 20 and 40 years but can occur earlier. Any part of the digestive system may be affected; the esophagus and colon (particularly the rectum, sigmoid colon, and descending colon) are the most frequently involved sites. Esophageal involvement is more common than colonic involvement [
         <a href="#rid13">
          13,20
         </a>
         ]. Disease progression is usually slow. In a retrospective study of 379 patients with the indeterminate chronic form followed up to 10 years, 100 (26.4 percent) and 87 (22.9 percent) progressed to digestive and cardiac forms, respectively. Female sex was the only independent predictor of progression to digestive forms (hazard ratio, 1.56).
         <a class="drug drug_general" data-topicid="114673" href="/z/d/drug information/114673.html" rel="external">
          Benznidazole
         </a>
         treatment was statistically protective for progression to cardiac, but not to digestive forms [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H86302870">
         <span class="h2">
          Esophageal manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Esophageal manifestations of Chagas disease are similar to patients with idiopathic achalasia. Patients with minor motility abnormalities may be asymptomatic but develop progressive dysphagia and regurgitation due to neuronal loss. Dysphagia occurs initially with solids but eventually also develops with liquids. Affected patients eat more slowly and often adopt specific maneuvers such as lifting the neck or throwing the shoulders back in order to enhance esophageal emptying. Regurgitation of bland undigested food or saliva is common and, in severe cases, may result in aspiration. As the disease progresses, food may become lodged in the esophagus and cause retrosternal pain due to local irritation, ulceration, bleeding, perforation, and fistulas. In end-stage disease, malnutrition can develop [
         <a href="#rid13">
          13
         </a>
         ]. Patients with megaesophagus also have an increased risk of esophageal cancer.
         <em>
          PIK3CA
         </em>
         gene mutations have been found to have a putative role in esophageal squamous cell carcinoma development in chagasic patients with megaesophagus [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">
          "Achalasia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H86302877">
         <span class="h2">
          Colonic manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Colonic involvement of Chagas disease results in progressive dilation. The sigmoid colon is dilated and elongated in nearly all cases of megacolon; the rectum is involved in 80 percent of cases. Dilation of more proximal colonic segments is rare. Intestinal constipation is one of the main reasons for seeking medical evaluation. Patients usually present with slowly progressive constipation until stool evacuation becomes almost impossible. As the disease progresses, patients may report several weeks between bowel movements. This may be accompanied by bloating and, less often, colicky abdominal pain. In a minority of patients, prolonged stool retention can lead to fecalith formation. Patients usually have mild abdominal discomfort or rectal fullness and can be diagnosed by abdominal palpation and rectal examination. Fecaloma-associated stercoral ulceration can occur, and overflow diarrhea can result from fecal retention. In rare cases, pseudo-obstruction results and volvulus can lead to secondary bowel ischemia. Anorexia and malnutrition can also develop.
        </p>
        <p>
         The prevalence of megacolon is not known because of diagnostic difficulties in remote areas. Symptoms may be absent in 25 to 30 percent of individuals with radiographic evidence of colonic dilatation. Most cases of megacolon are associated with megaesophagus [
         <a href="#rid3">
          3
         </a>
         ]. An increased frequency of colorectal cancer has not been reported in patients with megacolon [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H86302884">
         <span class="h2">
          Other manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other parts of the digestive tract can be involved, including the stomach, small bowel, biliary tree, and salivary glands. However, symptoms secondary to involvement of these organs is rare.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stomach
         </strong>
         – Approximately 20 percent of patients with megaesophagus have gastric involvement. Gastric manifestations may include altered myoelectrical activity (gastric dysrhythmias), alterations in gastric emptying, distension, hypoperistalsis, hypochlorhydria, and eventually pyloric hypertrophy [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Small intestine
         </strong>
         – Involvement of the small bowel (Chagas enteropathy) has also been reported, with or without dilatation. Small intestinal bacterial overgrowth and chronic intestinal pseudo-obstruction can cause abdominal pain, bloating, and distension [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">
          "Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Clinical features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2639.html" rel="external">
          "Chronic intestinal pseudo-obstruction: Etiology, clinical manifestations, and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biliary tract
         </strong>
         – Cholecystomegaly and choledochodilation are rare. An increased prevalence of cholelithiasis has been reported among patients with Chagas disease [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Salivary glands
         </strong>
         – Hypertrophy of the salivary glands develops in up to 25 percent of individuals with megaesophagus; the esophageal salivary reflex produces hypersalivation [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H903642183">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chagas gastrointestinal disease should be suspected in individuals with gastrointestinal symptoms who have lived in endemic countries of Latin America and those born to women from endemic countries. Symptoms consistent with gastrointestinal Chagas disease include dysphagia, odynophagia, regurgitation, progressive constipation, or its complications (eg, sigmoid volvulus and bowel ischemia). There is no diagnostic test to establish gastrointestinal involvement of Chagas disease. A presumptive diagnosis of Chagas disease can be made in patients with motor abnormalities that are consistent with Chagas disease and positive laboratory diagnosis of chronic Chagas disease. Issues related to laboratory diagnosis of chronic Chagas disease is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/114192.html" rel="external">
          "Chagas disease: Chronic Trypanosoma cruzi infection", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2484257630">
         <span class="h1">
          EVALUATION FOR GASTROINTESTINAL INVOLVEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a diagnosis of chronic
         <em>
          T. cruzi
         </em>
         infection by serologic testing should be assessed for the presence of gastrointestinal symptoms [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/114192.html" rel="external">
          "Chagas disease: Chronic Trypanosoma cruzi infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4144827959">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluation for gastrointestinal involvement may be considered in patients from countries where the gastrointestinal form of Chagas diseases is frequent (mainly the Southern Cone of South America) in the presence or absence of symptoms; megacolon and megaesophagus can be present in up to 20 percent of asymptomatic patients [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
         Whether to perform
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram and colon enema on every patient or to limit those studies only to patients with symptoms consistent with gastrointestinal Chagas disease depends on the prevalence of digestive involvement in the country of origin. Brazilian guidelines recommend a barium enema for all patients with chronic Chagas disease [
         <a href="#rid30">
          30
         </a>
         ]. Patients who are asymptomatic should be reassessed annually for gastrointestinal symptoms; each year approximately 2 percent of patients develop clinical manifestations of the disease and there are no known markers of disease progression. Symptoms consistent with gastrointestinal Chagas disease include dysphagia, odynophagia, regurgitation, weight loss, aspiration, cough, progressive constipation, or its complications (eg, fecaloma, sigmoid volvulus, and bowel ischemia) [
         <a href="#rid31">
          31
         </a>
         ]. Patients at risk for Chagas disease with proven achalasia should be tested for
         <em>
          T. cruzi
         </em>
         infection [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/114192.html" rel="external">
          "Chagas disease: Chronic Trypanosoma cruzi infection", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         In patients with upper gastrointestinal symptoms, we perform esophageal manometry and a
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram. In addition, we perform an upper endoscopy to exclude a malignancy at the esophagogastric junction that can mimic Chagas disease. (See
         <a class="local">
          'Patients with suspected esophageal involvement'
         </a>
         below.)
        </p>
        <p>
         Evaluation for colonic involvement due to Chagas disease consists of contrast-enhanced imaging (eg, computed tomography scan,
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         enema). In addition, we perform a colonoscopy to exclude a mechanical obstruction and complications associated with megacolon. Anorectal manometry can be considered but is not diagnostic and cannot distinguish Chagas from other causes of pelvic floor dyssynergia in constipation.
        </p>
        <p class="headingAnchor" id="H86302898">
         <span class="h2">
          Patients with suspected esophageal involvement
         </span>
        </p>
        <p class="headingAnchor" id="H166530877">
         <span class="h3">
          Barium esophagram
         </span>
         <span class="headingEndMark">
          —
         </span>
         Finding on
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram in patients with Chagas are similar to patients with idiopathic achalasia and include (see
         <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">
          "Achalasia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Barium esophagram'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dilation of the esophagus (
         <a class="graphic graphic_diagnosticimage graphicRef66813" href="/z/d/graphic/66813.html" rel="external">
          image 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Narrow esophagogastric junction with "bird-beak" appearance caused by the persistently contracted lower esophageal sphincter (LES)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aperistalsis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Delayed emptying of
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         (There is a linear correlation between the transit time and the grade of the megaesophagus, from 300 seconds in stage I to &gt;33,000 seconds in stage IV [
         <a href="#rid29">
          29
         </a>
         ].)
        </p>
        <p>
        </p>
        <p>
         Four stages of Chagas disease are recognized based on the findings on
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram noting the degree of megaesophagus and severity of motor abnormalities [
         <a href="#rid33">
          33
         </a>
         ]. The degree of megaesophagus is associated with the severity of dysphagia but does not reflect the duration of the disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage I (delayed emptying) – Normal diameter of esophagus (&lt;10 cm); minimal contrast retention; presence of a residual air column above the contrast
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage II (moderate esophageal enlargement with motor incoordination) – Moderate dilatation, with some contrast retention; increase in uncoordinated motor activity; relative hypertonicity of the inferior third of the esophagus
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage III (hypotonic and large achalasic esophagus) – Large increase in diameter and substantial contrast retention; hypotonic esophagus with weak or absent motor activity
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage IV (atonic esophagus) – Large increase in volume, atonic, elongated esophagus lying on the right diaphragmatic dome
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H343215449">
         <span class="h3">
          Esophageal manometry
         </span>
         <span class="headingEndMark">
          —
         </span>
         Esophageal manometry can provide quantitative information regarding esophageal function; changes in esophageal motility may be present even in asymptomatic patients [
         <a href="#rid2">
          2,34,35
         </a>
         ]. In addition, it can diagnose other motility disorders that can cause dysphagia. It is difficult to distinguish between idiopathic achalasia and achalasia secondary to Chagas by esophageal manometry; however, the LES pressure is usually low in patients with Chagas disease and high in patients with idiopathic achalasia [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Diagnostic manometric findings of achalasia include a nonrelaxing or partially relaxing LES and aperistalsis upon deglutition. (See
         <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">
          "Achalasia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Esophageal manometry'
         </a>
         .)
        </p>
        <p>
         Esophageal manometry can demonstrate mild esophageal motor abnormalities that are not detected by
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         swallow [
         <a href="#rid36">
          36
         </a>
         ]. In patients without esophageal dilation, nonspecific esophageal motor abnormalities include multipeaked peristaltic contractions, aperistalsis limited to the lower esophagus plus a relaxing LES, and total aperistalsis with a relaxing LES. The basal LES pressure in Chagas is usually normal or slightly lower than normal. However, in patients with achalasia and massive dilated megaesophagus there is not a well-defined manometric pattern (while the upper esophageal sphincter is hypotonic and has impaired relaxation in the majority of patients, the lower sphincter does not have a characteristic manometric pattern) [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H86302921">
         <span class="h3">
          Upper gastrointestinal endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Finding on upper endoscopy in patients with Chagas are similar to patients with idiopathic achalasia and include a dilated esophagus that contains residual material, sometimes in large quantities. The appearance of the LES may range from normal to a thickened muscular ring with a rosette configuration on retroflexed view. This technique has a very high sensitivity but a low specificity to diagnose megaesophagus.
        </p>
        <p>
         The following classification has been proposed for staging megaesophagus [
         <a href="#rid38">
          38
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage I – Greater salivary retention, presence of reduced peristaltic waves, and no dilatation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage II – Mild dilation with greater retention of liquids and possibly food residue
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage III – Upstream dilatation with difficulty of passage of the endoscope through the cardia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage IV – Clear esophageal tortuosity mainly in the distal third of the esophagus
        </p>
        <p>
        </p>
        <p>
         Histologic sections may demonstrate a nonspecific chronic inflammatory infiltrate, but parasites are rarely seen [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">
          "Achalasia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Upper endoscopy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H86302928">
         <span class="h2">
          Patients with suspected colonic involvement
         </span>
        </p>
        <p class="headingAnchor" id="H86302937">
         <span class="h3">
          Contrast radiography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Conventional abdominal radiography may demonstrate increased luminal air; fecaloma can also be visualized, if present. Findings suggestive of Chagas disease on contrast-enhanced abdominal imaging (eg, computed tomography scan, magnetic resonance imaging, or
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         enema) include decreased bowel haustra and a dilated, atonic colon [
         <a href="#rid40">
          40
         </a>
         ]. Dilatation usually occurs in the distal colon, including sigmoid and rectum; rarely, dilatation occurs in other segments or in the entire colon. Megacolon is defined as a sigmoid colon or descending colon diameter &gt;6.5 cm, ascending colon &gt;8 cm in diameter, or cecum &gt;12 cm in diameter. Dilatation is frequently associated with an increase in colon length. Dolichocolon is defined as a length from the anus to the transition to the descending colon &gt;70 cm.
        </p>
        <p>
         Three radiographic stages have been proposed [
         <a href="#rid33">
          33
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage 0 – No alterations in
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         enema
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage I – Dolichocolon
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage II – Dolichomegacolon
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H241296471">
         <span class="h3">
          Colonoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Finding on colonoscopy in patients with Chagas are nonspecific. Histology may demonstrate a nonspecific chronic inflammatory infiltrate, but parasites are rarely seen.
        </p>
        <p class="headingAnchor" id="H86302944">
         <span class="h3">
          Anorectal manometry
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main findings are anorectal motor dysfunction and abnormal anorectal inhibitory reflex (a normal anorectal inhibitory reflex is defined as sphincter pressure drop superior to 20 mmHg below the resting pressure). However, these motor abnormalities are nonspecific and are seen in patients with chronic constipation [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13928261">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of esophageal motility abnormality associated with Chagas disease includes primary idiopathic achalasia and malignancy (pseudoachalasia). Esophageal involvement in Chagas disease can be differentiated from primary idiopathic achalasia by serology and from pseudoachalasia due to an esophagogastric malignancy with upper endoscopy. (See
         <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">
          "Achalasia: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Megacolon can result from neurologic (eg, Parkinson disease, diabetic neuropathy), metabolic disorders, and systemic diseases (eg, systemic sclerosis). Other causes of colonic dilation include Ogilvie syndrome, mechanical obstruction, and toxic megacolon. Patients with mechanical obstruction and Ogilvie syndrome frequently complain of crampy abdominal pain. A "cut-off sign" (lack of gas in the distal colon or rectum) or small bowel air-fluid levels may be seen on abdominal radiographs. In patients with a mechanical obstruction, an obstructing lesion can be visualized with contrast enema. (See
         <a class="medical medical_review" href="/z/d/html/2531.html" rel="external">
          "Acute colonic pseudo-obstruction (Ogilvie's syndrome)"
         </a>
         .)
        </p>
        <p>
         Patients with toxic megacolon have evidence of significant systemic toxicity with fever, tachycardia, altered sensorium, and abdominal pain. Patients with toxic megacolon often have a history of severe bloody diarrhea or other signs or symptoms of chronic inflammatory bowel disease. On abdominal upright and plain films, there is evidence of colonic distension, but the normal colonic haustral pattern is either absent or severely disturbed with "thumb-printing" due to the presence of submucosal edema or thickening of the colonic wall. (See
         <a class="medical medical_review" href="/z/d/html/1381.html" rel="external">
          "Toxic megacolon"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H86302958">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antitrypanosomal therapy has not been proven to affect progression of gastrointestinal disease [
         <a href="#rid21">
          21,41-43
         </a>
         ]. Management focuses on symptom amelioration (dysphagia in the case of megaesophagus and constipation in the case of megacolon) [
         <a href="#rid30">
          30,44
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Megaesophagus
         </strong>
         – The management of megaesophagus is similar to patients with idiopathic achalasia and is aimed at decreasing the resting pressure in the lower esophageal sphincter (LES) to a level at which the sphincter no longer impedes the passage of ingested material. Treatment approaches include dietary measures, pharmacologic treatment, and endoscopic/surgical interventions. Dietary measures for all patients with achalasia include eating slowly in an upright position, chewing food well, avoiding hard and dry foods, drinking water during or after meals (as that may aid with food ingestion), and avoiding lying down shortly after eating.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with stage I and II may have a good response with dietary changes and pharmacologic treatment. Pharmacologic therapy with isosorbide and
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         are effective in reducing esophageal symptoms by lowering esophageal sphincter pressure; isosorbide appears to be more effective, however, nifedipine appears to be better tolerated [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with stage III and IV, and some with stage I and II, nonresponsive to dietary changes and/or pharmacologic treatment, usually require additional intervention.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with advanced-stage megaesophagus (stage IV) who have average surgical risk, preferred options for treatment include laparoscopic Heller myotomy with a partial fundoplication, and peroral endoscopic myotomy (POEM) [
         <a href="#rid36">
          36
         </a>
         ]. In Chagas patients with achalasia, POEM may be more effective than surgical myotomy [
         <a href="#rid46">
          46
         </a>
         ]. However, the choice of initial procedure depends on local expertise. If laparoscopic myotomy or POEM fails to improve symptoms, a more complex surgical procedure is required (eg, esophagectomy) [
         <a href="#rid13">
          13,47
         </a>
         ]. Pneumatic dilation is an option for patients with stage I to III disease but should be avoided in stage IV due to the risk of perforation. (See
         <a class="local">
          'Esophageal manifestations'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2261.html" rel="external">
          "Overview of the treatment of achalasia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15060.html" rel="external">
          "Surgical myotomy for achalasia", section on 'Sigmoid megaesophagus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Since basal lower esophageal sphincter pressure is already lessened in most Chagasic patients with megaesophagus, the endoscopic injection of botulinum toxin is expected to have a minimal effect on them. There is no study on the long-term effects of this approach in a large number of Chagas disease patients [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Megacolon
         </strong>
         – Constipation due to megacolon can be improved with physical activity, a high-fiber diet, abundant fluid intake, pharmacologic therapy (eg, osmotic laxatives), and intermittent enemas or suppositories with glycerol [
         <a href="#rid49">
          49
         </a>
         ]. Fecal impaction requires manual disimpaction. Indications for surgical intervention include severe persistent constipation refractory to medical therapy or complications secondary to fecalomas (eg, sigmoid volvulus, stercoral ulcer). Options for surgical intervention include rectosigmoidectomy with retrocecal interpositioning or rectosigmoidectomy with end-to-side low colorectal anastomosis [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1223486681">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113058.html" rel="external">
          "Society guideline links: Chagas disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1998544854">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/97518.html" rel="external">
          "Patient education: Chagas disease (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3661108">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology –
         </strong>
         Chagas disease is caused by infection with the protozoan parasite
         <em>
          Trypanosoma cruzi
         </em>
         . Transient gastrointestinal symptoms can occur during the acute phase of infection. However, significant gastrointestinal manifestations of Chagas disease are mainly associated with the chronic phase of infection. The likelihood of digestive involvement may vary by geographic region. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis –
         </strong>
         The pathogenesis of disease consists of destruction of the neurons of the enteric nervous system. Uncoordinated motor activity of the sphincters occurs as a result of denervation. In the esophagus, there is hypercontractility and increased muscular tone, and often there is failure of sphincter relaxation with swallowing. In the large intestine, there is abnormal basal colonic motility and impaired relaxation of the anal sphincter. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations –
         </strong>
         The onset of symptoms is most common between the ages of 20 and 40 years but can occur earlier. Any part of the digestive system may be affected; the esophagus and colon (particularly the rectum, sigmoid colon, and descending colon) are the most frequently involved sites. Clinical manifestations of gastrointestinal Chagas disease include dysphagia, odynophagia, regurgitation, progressive constipation, and its complications (eg, sigmoid volvulus and bowel ischemia). (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation for gastrointestinal involvement –
         </strong>
         Patients with a diagnosis of chronic
         <em>
          T. cruzi
         </em>
         infection by serologic testing should be assessed for the presence of gastrointestinal symptoms. Evaluation for gastrointestinal involvement is indicated in patients with symptoms consistent with gastrointestinal Chagas disease. Whether to perform
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram and colon enema on every patient or to limit those studies only to patients with symptoms consistent with gastrointestinal Chagas disease depends on the prevalence of digestive involvement in the country of origin. There is no diagnostic test to establish gastrointestinal involvement of Chagas disease. The tests performed for evaluation of gastrointestinal involvement of Chagas disease can diagnose motor abnormalities that are consistent with but not specific to Chagas disease. (See
         <a class="local">
          'Evaluation for gastrointestinal involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Our approach to diagnosis –
         </strong>
         In patients with symptoms suggestive of upper gastrointestinal Chagas (eg, dysphagia, odynophagia, regurgitation), we perform esophageal manometry and a
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram. In addition, we perform an upper endoscopy to exclude a malignancy at the esophagogastric junction that can mimic Chagas disease. In patients with lower gastrointestinal symptoms, evaluation for colonic involvement due to Chagas disease consists of contrast-enhanced imaging (eg, computed tomography scan or barium enema) and anorectal manometry. In addition, we perform a colonoscopy to exclude a mechanical obstruction and complications associated with megacolon. (See
         <a class="local">
          'Our approach'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/114192.html" rel="external">
          "Chagas disease: Chronic Trypanosoma cruzi infection", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management -
         </strong>
         There are insufficient data to support that treatment with antitrypanosomal drugs affects progression of digestive Chagas disease. We suggest
         <strong>
          not
         </strong>
         administering antitrypanosomal therapy for patients with Chagas gastrointestinal disease (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); management focuses on symptom amelioration. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7650056">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge Caryn Bern, MD, MPH, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bern C. Chagas' Disease. N Engl J Med 2015; 373:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-Ayala A, Pérez-Molina JA, Norman F, et al. Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis. Ann Trop Med Parasitol 2011; 105:25.
          </a>
         </li>
         <li class="breakAll">
          Rezende JM, Luquetti AO. Chagasic megavisceras. In: Nervous System in Chagas Disease, Pan American Health Organization, Washington 1994. p.149.
         </li>
         <li class="breakAll">
          Rassi A, Rezende JM, Luquetti AO, et al. Clinical phases and forms of Chagas disease. In: American trypanosomiasis (Chagas disease): One hundred years of research, 1st ed, Telleria J, Tibayrenc M (Eds), Elsevier, Burlington, MA 2010. p.709.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miles MA, Cedillos RA, Póvoa MM, et al. Do radically dissimilar Trypanosoma cruzi strains (zymodemes) cause Venezuelan and Brazilian forms of Chagas' disease? Lancet 1981; 1:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bierrenbach AL, Quintino ND, Moreira CHV, et al. Hospitalizations due to gastrointestinal Chagas disease: National registry. PLoS Negl Trop Dis 2022; 16:e0010796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Montalvá A, Salinas C, Sullerio E, et al. Risk of Trypanosoma cruzi infection among travellers visiting friends and relatives to continental Latin America. PLoS Negl Trop Dis 2021; 15:e0009528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           da Silveira AB, Arantes RM, Vago AR, et al. Comparative study of the presence of Trypanosoma cruzi kDNA, inflammation and denervation in chagasic patients with and without megaesophagus. Parasitology 2005; 131:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinto L, Schijman AG, Alonso-Padilla J, et al. Molecular detection and parasite load of Trypanosoma cruzi in digestive tract tissue of Chagas disease patients affected by megacolon. Acta Trop 2022; 235:106632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vazquez BP, Vazquez TP, Miguel CB, et al. Inflammatory responses and intestinal injury development during acute Trypanosoma cruzi infection are associated with the parasite load. Parasit Vectors 2015; 8:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miles MA, Feliciangeli MD, de Arias AR. American trypanosomiasis (Chagas' disease) and the role of molecular epidemiology in guiding control strategies. BMJ 2003; 326:1444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Troncon LE, Oliveira RB, Romanello LM, et al. Abnormal progression of a liquid meal through the stomach and small intestine in patients with Chagas' disease. Dig Dis Sci 1993; 38:1511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Oliveira RB, Troncon LE, Dantas RO, Menghelli UG. Gastrointestinal manifestations of Chagas' disease. Am J Gastroenterol 1998; 93:884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamiji MM, de Oliveira RB. [Features of Chagas' disease patients with emphasis on digestive form, in a tertiary hospital of Ribeirão Preto, SP]. Rev Soc Bras Med Trop 2005; 38:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           do Carmo Neto JR, Braga YLL, da Costa AWF, et al. Biomarkers and Their Possible Functions in the Intestinal Microenvironment of Chagasic Megacolon: An Overview of the (Neuro)inflammatory Process. J Immunol Res 2021; 2021:6668739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pereira NS, Queiroga TBD, da Silva DD, et al. NOD2 receptor is crucial for protecting against the digestive form of Chagas disease. PLoS Negl Trop Dis 2020; 14:e0008667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Souza-Basqueira M, Ribeiro RM, de Oliveira LC, et al. Gut Dysbiosis in Chagas Disease. A Possible Link to the Pathogenesis. Front Cell Infect Microbiol 2020; 10:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rassi A, Rezende JM. [Clinical and radiological evaluation of the esophagus and colon in the acute phase of Chagas disease with Report of three cases of spontaneous remission of esophageal group I aperistalsis]. Rev Soc Bras Med Trop 2011; 44:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souza-Lima Rde C, Barbosa Md, Coura JR, et al. Outbreak of acute Chagas disease associated with oral transmission in the Rio Negro region, Brazilian Amazon. Rev Soc Bras Med Trop 2013; 46:510.
          </a>
         </li>
         <li class="breakAll">
          Rezende JM, Moreira H. Forma digestive da Doenca de Chagas. In: Trypanosoma cruzi e Doeca de Chagas, 2nd ed, Brener Z, Andrade ZA, Barral-Neto N (Eds), Guanabara Koogan, Rio de Janeiro 2000. p.465.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nunes da Costa EAP, Victória C, Fortaleza CMCB. Predictors of development of cardiac and digestive disorders among patients with indeterminate chronic Chagas Disease. PLoS Negl Trop Dis 2021; 15:e0009680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munari FF, Cruvinel-Carloni A, Lacerda CF, et al. PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome. Infect Agent Cancer 2018; 13:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirchhoff LV. American trypanosomiasis (Chagas' disease). Gastroenterol Clin North Am 1996; 25:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rezende Filho J, De Rezende JM, Melo JR. Electrogastrography in patients with Chagas' disease. Dig Dis Sci 2005; 50:1882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meneghelli UG. Chagasic enteropathy. Rev Soc Bras Med Trop 2004; 37:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martini AS, Lopes RA, Utrilla LS, et al. Morphological and morphometric study of the alterations on young mouse parotid gland with subpatent Chagas' disease. Angew Parasitol 1986; 27:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-Molina JA, Molina I. Chagas disease. Lancet 2018; 391:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvador F, Mego M, Sánchez-Montalvá A, et al. Assessment of rectocolonic morphology and function in patients with Chagas disease in Barcelona (Spain). Am J Trop Med Hyg 2015; 92:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martins P, Ferreira CS, Cunha-Melo JR, Professor Emeritus of Surgery. Esophageal transit time in patients with chagasic megaesophagus: Lack of linear correlation between dysphagia and grade of dilatation. Medicine (Baltimore) 2018; 97:e0084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dias JC, Ramos AN Jr, Gontijo ED, et al. 2 nd Brazilian Consensus on Chagas Disease, 2015. Rev Soc Bras Med Trop 2016; 49Suppl 1:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattoso LF, Reeder MM. Radiological diagnosis of Chagas' disease (American trypanosomiasis). Semin Roentgenol 1998; 33:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panesso-Gómez S, Pavia P, Rodríguez-Mantilla IE, et al. Trypanosoma cruzi Detection in Colombian Patients with a Diagnosis of Esophageal Achalasia. Am J Trop Med Hyg 2018; 98:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de REZENDE J, LAUAR KM, de OLIVEIRA A. [Clinical and radiological aspects of aperistalsis of the esophagus]. Rev Bras Gastroenterol 1960; 12:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roure S, Valerio L, Vallès X, et al. Oesophageal motility disorders in infected immigrants with Chagas disease in a non-endemic European area. United European Gastroenterol J 2016; 4:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Montalvá A, Moris M, Mego M, et al. High Resolution Esophageal Manometry in Patients with Chagas Disease: A Cross-Sectional Evaluation. PLoS Negl Trop Dis 2016; 10:e0004416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dantas RO, Godoy RA, Oliveira RB, et al. Lower esophageal sphincter pressure in Chagas' disease. Dig Dis Sci 1990; 35:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menezes MA, Andolfi C, Herbella FA, Patti MG. High-resolution manometry findings in patients with achalasia and massive dilated megaesophagus. Dis Esophagus 2017; 30:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barros F, Soares JCA, Barros FP, et al. Agreement between upper endoscopy and esophagography in the diagnosis of megaesophagus in Chagas disease. Rev Soc Bras Med Trop 2019; 52:e20180258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinazo MJ, Cañas E, Elizalde JI, et al. Diagnosis, management and treatment of chronic Chagas' gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterol Hepatol 2010; 33:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez EB, Rezende JM, Macedo V, Castro N. Estudo radiológico do cólon em indivíduos de área endemica de doenca de Chagas atraves da técnica simplificada de Ximenes. Rev Soc Bras Med Trop 2002; 35 Suppl III:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007; 298:2171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011; 364:2527.
          </a>
         </li>
         <li class="breakAll">
          Pan American Health Organization. Guidelines for the diagnosis and treatment of Chagas disease. Washington, D.C.: PAHO; 2019. http://iris.paho.org/xmlui/bitstream/handle/123456789/49653/9789275120439_eng.pdf?sequence=6&amp;isAllowed=y (Accessed on July 08, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antinori S, Galimberti L, Bianco R, et al. Chagas disease in Europe: A review for the internist in the globalized world. Eur J Intern Med 2017; 43:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borges Migliavaca C, Stein C, Colpani V, et al. Isosorbide and nifedipine for Chagas' megaesophagus: A systematic review and meta-analysis. PLoS Negl Trop Dis 2018; 12:e0006836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahaleh M, Tyberg A, Suresh S, et al. How does per-oral endoscopic myotomy compare to Heller myotomy? The Latin American perspective. Endosc Int Open 2020; 8:E1392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costa LCDS, Braga JGR, Tercioti Junior V, et al. Surgical treatment of relapsed megaesophagus. Rev Col Bras Cir 2020; 47:e20202444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brant C, Moraes-Filho JP, Siqueira E, et al. Intrasphincteric botulinum toxin injection in the treatment of chagasic achalasia. Dis Esophagus 2003; 16:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teza DCB, Ferreira ÉC, Gomes ML. BOWEL FREQUENCY AND SYMPTOMS OF CONSTIPATION AND ITS RELATION WITH THE LEVEL OF PHYSICAL ACTIVITY IN PATIENTS WITH CHAGAS DISEASE. Arq Gastroenterol 2020; 57:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutait DE, Cutait R. Surgery of chagasic megacolon. World J Surg 1991; 15:188.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5700 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26222561" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Chagas' Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21294946" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21294946" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21294946" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6113312" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Do radically dissimilar Trypanosoma cruzi strains (zymodemes) cause Venezuelan and Brazilian forms of Chagas' disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36121897" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hospitalizations due to gastrointestinal Chagas disease: National registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34214087" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Risk of Trypanosoma cruzi infection among travellers visiting friends and relatives to continental Latin America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16255821" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Comparative study of the presence of Trypanosoma cruzi kDNA, inflammation and denervation in chagasic patients with and without megaesophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35932843" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Molecular detection and parasite load of Trypanosoma cruzi in digestive tract tissue of Chagas disease patients affected by megacolon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25889515" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Inflammatory responses and intestinal injury development during acute Trypanosoma cruzi infection are associated with the parasite load.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12829559" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : American trypanosomiasis (Chagas' disease) and the role of molecular epidemiology in guiding control strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8344109" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Abnormal progression of a liquid meal through the stomach and small intestine in patients with Chagas' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9647012" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Gastrointestinal manifestations of Chagas' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16082476" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : [Features of Chagas' disease patients with emphasis on digestive form, in a tertiary hospital of Ribeirão Preto, SP].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33928170" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Biomarkers and Their Possible Functions in the Intestinal Microenvironment of Chagasic Megacolon: An Overview of the (Neuro)inflammatory Process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32986710" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : NOD2 receptor is crucial for protecting against the digestive form of Chagas disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32974213" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Gut Dysbiosis in Chagas Disease. A Possible Link to the Pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21340412" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : [Clinical and radiological evaluation of the esophagus and colon in the acute phase of Chagas disease with Report of three cases of spontaneous remission of esophageal group I aperistalsis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23681429" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Outbreak of acute Chagas disease associated with oral transmission in the Rio Negro region, Brazilian Amazon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23681429" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Outbreak of acute Chagas disease associated with oral transmission in the Rio Negro region, Brazilian Amazon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34388146" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Predictors of development of cardiac and digestive disorders among patients with indeterminate chronic Chagas Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30619505" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8863038" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : American trypanosomiasis (Chagas' disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16187192" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Electrogastrography in patients with Chagas' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15330067" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Chagasic enteropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3090907" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Morphological and morphometric study of the alterations on young mouse parotid gland with subpatent Chagas' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28673423" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Chagas disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25778503" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Assessment of rectocolonic morphology and function in patients with Chagas disease in Barcelona (Spain).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29517674" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Esophageal transit time in patients with chagasic megaesophagus: Lack of linear correlation between dysphagia and grade of dilatation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27982292" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : 2 nd Brazilian Consensus on Chagas Disease, 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9516687" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Radiological diagnosis of Chagas' disease (American trypanosomiasis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29405099" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Trypanosoma cruzi Detection in Colombian Patients with a Diagnosis of Esophageal Achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13741121" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : [Clinical and radiological aspects of aperistalsis of the esophagus].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27536373" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Oesophageal motility disorders in infected immigrants with Chagas disease in a non-endemic European area.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26848957" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : High Resolution Esophageal Manometry in Patients with Chagas Disease: A Cross-Sectional Evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2108007" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Lower esophageal sphincter pressure in Chagas' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28375440" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : High-resolution manometry findings in patients with achalasia and massive dilated megaesophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30843966" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Agreement between upper endoscopy and esophagography in the diagnosis of megaesophagus in Chagas disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19837482" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Diagnosis, management and treatment of chronic Chagas' gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Estudo radiológico do cólon em indivíduos deárea endemica de doenca de Chagas atraves da técnica simplificada de Ximenes
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18000201" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Evaluation and treatment of chagas disease in the United States: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21714649" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Antitrypanosomal therapy for chronic Chagas' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21714649" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Antitrypanosomal therapy for chronic Chagas' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28502864" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Chagas disease in Europe: A review for the internist in the globalized world.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30265663" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Isosorbide and nifedipine for Chagas' megaesophagus: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33015342" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : How does per-oral endoscopic myotomy compare to Heller myotomy? The Latin American perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32520130" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Surgical treatment of relapsed megaesophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12581252" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Intrasphincteric botulinum toxin injection in the treatment of chagasic achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32609158" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : BOWEL FREQUENCY AND SYMPTOMS OF CONSTIPATION AND ITS RELATION WITH THE LEVEL OF PHYSICAL ACTIVITY IN PATIENTS WITH CHAGAS DISEASE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1903231" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Surgery of chagasic megacolon.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
